Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabolon, a diagnostics and services company, and the University of Michigan have signed an agreement for the commercial development of prostate cancer diagnostics.
Subscribe to our email newsletter
The agreement puts in place a number of activities to help progress Metabolon’s Prostarix line of prostate cancer diagnostics including an exclusive license for Metabolon to use prostate cancer aggressitivity markers that were discovered in a collaborative research project between the University of Michigan and Metabolon.
This intellectual property will provide the company with a significant competitive advantage in the field of prostate cancer diagnosis and will serve as the basis for Prostarix-which is expected to be launched in late 2009.
The agreement also includes a sponsored research agreement with Arun Sreekumar, assistant professor of pathology at the University of Michigan, aimed at a deeper understanding into the role the biomarkers play in the onset of aggressiveness.
John Ryals, CEO of Metabolon, said: “Metabolon continues to work with researchers like those at the University of Michigan to develop easy-to-use diagnostic tools to better understand aggressiveness and metastatic potential of prostate cancer and to help doctors and patients make critical treatment decisions.”